Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026)

Design Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $390.6 million for Q4 2021.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 969.55% to $390.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.6 billion, a 4303.3% increase, with the full-year FY2021 number at $390.6 million, up 969.55% from a year prior.
  • Liabilities and Shareholders Equity hit $390.6 million in Q4 2021 for Design Therapeutics, down from $400.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for DSGN hit a ceiling of $411.9 million in Q1 2021 and a floor of $36.5 million in Q4 2020.